Search

Your search keyword '"Turville, Stuart"' showing total 263 results

Search Constraints

Start Over You searched for: Author "Turville, Stuart" Remove constraint Author: "Turville, Stuart" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
263 results on '"Turville, Stuart"'

Search Results

1. Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

2. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents

4. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

5. Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients

7. The HIV-1 proviral landscape reveals Nef contributes to HIV-1 persistence in effector memory CD4+ T-cells

8. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion

9. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

12. Boosting immunity: synergistic antiviral effects of luteolin, vitamin C, magnesium and zinc against SARS-CoV-2 3CLpro.

13. Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial.

14. A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection

16. The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory [CD4.sup.+] T cells

17. Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection

18. A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein

19. Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core

20. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants

21. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level

22. Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs

23. A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein

24. High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells

25. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

27. Abstract CT259: Comprehensive humoral and cellular immune assessments to SARS-CoV-2 (wild type, delta and omicron) following two- and three-dose vaccination schedule in a large adult cancer population: SerOzNET study: placeholder abstract

28. Abstract CT567: Comprehensive measures of COVID-19 vaccine efficacy in adolescent cancer patients: Results from SerOzNET

29. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV ‐2 variants, but preserved antigen‐specific T cell responses

31. High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens

32. Host glycocalyx captures HIV proximal to the cell surface via oligomannose-GlcNAc glycan-glycan interactions to support viral entry

33. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses

34. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses

35. Additional file 3 of Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)

36. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell responses

37. Additional file 1 of Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)

38. Additional file 2 of Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)

40. Carrageenan/MIV-150 (PC-815), a Combination Microbicide

42. Antiviral cyclic peptides targeting the main protease of SARS-CoV-2

43. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability

44. Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia

45. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell responses.

46. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

48. Modular Lentiviral Vectors for Highly Efficient Transgene Expression in Resting Immune Cells

49. Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display

50. Lentiviral System for Gene Delivery into Resting T-cells

Catalog

Books, media, physical & digital resources